FMS — Q2 2026 Earnings Preview
Setup in one line
Q1 was headline weak, underlying constructive by design: reported revenue EUR 4.612B (−5.5% YoY) but organic +3.9%; OI ex-SI EUR 467M (+10% cc) while reported OI EUR 286M absorbed FME25+ specials. Management confirmed (did not raise) flat FY26 revenue and +/− MSD% OI ex-SI — banking H1 strength for H2 TDAPA roll-off.
Fresenius Medical Care (FMS ADR / XTRA: FME) is a dialysis services + products franchise in year-two of the FME25+ transformation. 2026 is explicitly a transition year: VBC risk-contracting reset (~EUR 300M), divestitures, FX, and TDAPA/ACA regulatory headwinds mask organic progress. The investment debate is no longer “did FME25 work” — it is whether FME25+ + HDF + RCM can bridge the H2 TDAPA cliff and set up positive growth in 2027.
Growth trajectory — headline soft, organic and ex-SI constructive. The last print (Q1 2026, reported 2026-05-05) delivered total net revenue EUR 4.612B (−5.5% YoY reported) with organic growth +3.9%. Reported operating income EUR 286M; OI ex-SI EUR 467M grew ~+10% constant currency (company/review) with OI margin ex-SI 10.1%. FME25+ delivered EUR 50M of the EUR 250M FY26 savings target in Q1 (ahead of linear pace). No raise at Q1 — deliberate banking for H2 TDAPA.
Key watch items into Q2 2026:
- Organic growth durability vs. the confirmed broadly flat reported-revenue guide (organic +LSD offset by VBC / divestiture / FX).
- FME25+ savings pace: EUR 250M FY26; EUR 50M already booked in Q1 — stay ahead of linear.
- Regulatory bridge: EUR 150–200M headwind (phosphate binder TDAPA ~EUR 100M+ + ACA ~EUR 50M) — H2 gets harder; Q2 is still in the “H1 constructive” half.
- OI ex-SI path: guide +/− MSD% vs FY25 base EUR 2,212M; H1 positive / H2 negative framing.
- ADR vs EUR noise: Street ~$0.62 EPS / ~$5.47B sales is ADR $ — always translate carefully; company reports in EUR.
Classification: CONSERVATIVE confirmer (no raise at Q1), MIXED headline / solid ex-SI historically. Thesis: transition year — judge organic + OI ex-SI, not headline; H2 harder on TDAPA.
How to read FME "guidance": Fresenius Medical Care guides full-year revenue (broadly flat), OI ex-SI (+/− MSD%), savings, regulatory headwinds, and tax — not quarterly EPS. There is no Q2 2026 EUR guide to parse — the print is measured against (a) the confirmed FY2026 framework and (b) sell-side ADR $ consensus (~$0.62 EPS / ~$5.47B sales per FMP).
| FY2026 guide | Guide | Q1 update | FY2025 actual | Read-through |
|---|---|---|---|---|
| Revenue | Broadly flat vs FY25 (EUR/USD 1.18) | Confirmed · not raised | EUR 19.628B | Organic +LSD offset by VBC / divest / FX |
| OI ex-SI | +/− MSD% vs base | Confirmed | EUR 2,212M | H1+/H2− TDAPA path |
| FME25+ savings | EUR 250M | EUR 50M in Q1 | — | Ahead of linear pace |
| FME25+ one-time costs | ~EUR 350M | Tracking | — | Transformation investment (reported OI drag) |
| Regulatory headwind | EUR 150–200M | Confirmed | — | H2 weighted (TDAPA + ACA) |
| Strategic investments | EUR 100–150M | Confirmed | — | 5008X / HDF + SAP |
| Tax rate | 22–24% | Confirmed | — | Stable band |
| Raise at Q1? | — | No | — | Banking for H2 TDAPA by design |
Why no raise: management is deliberately banking Q1 outperformance (OI ex-SI +10% cc, savings front-loaded) to absorb the H2 TDAPA binder roll-off. That is the correct transformation-year posture — but it means Street and the market will not get a classic “beat and raise” narrative in H1. Q2 is a checkpoint, not a re-rate catalyst, unless organic or savings clearly beat and H2 language softens.
Q2 2026 Street (FMP ADR $): EPS ~$0.62 · Revenue ~$5.47B. Flag: ADR $ vs company EUR reporting — do not mix units without FX.
3a. Current quarter (Q2 2026) — consensus vs. Q2 2025 comp
FME does not guide the quarter; columns show ADR Street, the prior-year EUR comp, and FY framing. Prefer organic + OI ex-SI over reported revenue.
| Metric | Q2'25 actual (comp) | Q2'26 consensus | YoY / note | Framing |
|---|---|---|---|---|
| Net revenue | EUR 4.792B | ~$5.47B (ADR $) | Units differ — FX | Judge organic; Q1 organic +3.9% |
| Reported OI | EUR 425M | n/a (Street EPS-led) | — | Specials distort; use OI ex-SI |
| OI ex-SI | n/a (series from Q3'25) | n/a | Q1 +10% cc | Core earnings lens; FY +/− MSD% |
| EPS | ADR ~$0.52 (print) | ~$0.62 (ADR) | ADR $ | Headline can miss while ex-SI holds |
Note — reported vs. adjusted / ADR vs EUR: Q1 reported OI of EUR 286M absorbed material FME25+ specials vs OI ex-SI EUR 467M. Q1 was the first visible ADR headline miss after a long beat streak — by design. Always map FMP ADR $ estimates back to EUR company metrics before calling beat/miss on fundamentals.
3b. Historical quarterly trend (Daloopa) — 8 quarters + YoY
Revenue presented as EUR B (source series in EUR thousands / millions as filed). OI ex-SI series begins later; organic growth is the quality top-line read.
| Metric | Q2'24 | Q3'24 | Q4'24 | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 |
|---|---|---|---|---|---|---|---|---|
| Net revenue (EUR B) | 4.766 | 4.760 | 5.085 | 4.881 | 4.792 | 4.885 | 5.070 | 4.612 |
| Reported rev YoY % | — | — | — | — | +0.5% | +2.6% | −0.3% | −5.5% |
| Organic growth | +2% | +2% | — | +5% | +7% | +10% | FY25 +8% | +3.9% |
| Reported OI (EUR M) | 425 | 463 | 259 | 331 | 425 | 477 | 594 | 286 |
| Reported OI YoY % | — | — | — | — | 0% | +3.0% | +129% | −13.6% |
| OI ex-SI (EUR M) | — | — | — | — | — | 574 | 705 | 467 |
| OI margin ex-SI | — | — | — | — | — | — | — | 10.1% |
FY2025 anchors: Net revenue EUR 19.628B · OI ex-SI EUR 2,212M · Organic +8%.
Interpretation: reported revenue is a poor quality signal in 2026 — Q1'26 −5.5% YoY coexists with organic +3.9% because of FX, LatAm divestiture, and the VBC risk-contracting reset. Organic accelerated through 2025 (Q2 +7%, Q3 +10%, FY +8%) then stepped down to +3.9% in Q1'26 as transition items hit. Reported OI is volatile (Q4'24 trough 259 → Q4'25 peak 594 → Q1'26 286 on specials). The investable trajectory is organic + OI ex-SI (Q1 OI ex-SI 467, margin 10.1%, +10% cc).
3c. FQ+1 (H2 2026) and FY bridge
| Period | Revenue | OI / EPS | Note |
|---|---|---|---|
| Q2 2026 (Street ADR) | ~$5.47B | ~$0.62 EPS | FMP ADR $; still in H1 constructive half |
| H2 2026 | Harder | TDAPA roll-off | Phosphate binder TDAPA mid-year cliff; guide integrity test |
| FY2026 guide | Broadly flat | OI ex-SI +/− MSD% | Confirmed at Q1; not raised |
| FY+1 / multi-year | FME25+ + HDF | Cum. savings path | Cumulative FME25+ toward EUR 1.2B by end-2027 is the bridge |
The setup in one paragraph: management enters Q2 having confirmed, not raised, the full-year 2026 framework after a Q1 that was deliberately telegraphed as transition-year optics. Tone is muted and transformation-first: credibility of FME25+ savings and organic durability matter more than near-term ADR headline beats. The core bull points (EUR 50M Q1 savings of EUR 250M target, OI ex-SI +10% cc, 5008X/HDF rollout) are intact. The year still depends on banking H1 strength for H2 TDAPA — Q2 is the last clean checkpoint before that cliff becomes the narrative center.
Tone trajectory: FME25 delivery through 2025 built confidence → Q1'26 messaging is deliberately non-celebratory despite solid ex-SI. Refusal to raise on Q1 strength is the talented-management signal for a known H2 headwind — but it also means no easy re-rate catalyst in H1. Operational watch: US same-market treatment growth was soft in Q1 (−37 bps); organic +3.9% must not slip further if the flat-revenue guide is to remain comfortable.
Management-quality read: consistent FME25 → FME25+ communication, leverage at low end of 2.5–3.0x band, buyback program completing ahead of schedule (per Q1 review). Peers: DaVita (DVA) for US dialysis services color; products peers less liquid. Judge FMS on EUR company metrics, not ADR print-day noise.
| FY2026 metric | Status at Q1'26 | Confidence into Q2 | Why |
|---|---|---|---|
| Revenue broadly flat | Confirmed | Medium | Reported −5.5% in Q1; organic +3.9% must hold for guide math |
| OI ex-SI +/− MSD% | Confirmed | Medium · H2-loaded risk | Q1 +10% cc banks cushion; TDAPA cliff still ahead |
| FME25+ EUR 250M savings | EUR 50M in Q1 | Medium-high | Ahead of linear; credibility scorecard each print |
| Regulatory EUR 150–200M | Confirmed | H2 risk | TDAPA + ACA; Q2 still pre-cliff |
| Tax 22–24% | Confirmed | High | Low-variance item |
What to listen for on Aug 4 (tone tells):
(1) Organic growth — hold ~4%+ or slip toward flat? (2) FME25+ savings pace vs EUR 250M. (3) Any change in H2 TDAPA language (still banking, or softens)? (4) OI ex-SI trajectory and margin vs Q1 10.1%. (5) US same-market treatment growth recovery vs Q1 softness. (6) 5008X/HDF clinic and treatment milestones. (7) Guide: reaffirm expected; raise would be a positive surprise; cut is thesis risk.
| Catalyst | Latest KPI | Expectation into Q2'26 | Direction |
|---|---|---|---|
| FME25+ savings delivery | EUR 50M of EUR 250M FY26 in Q1 | Stay ahead of linear pace; cumulative path to 2027 | Positive |
| Organic growth durability | Q1 +3.9% vs FY25 +8% | Hold LSD–MSD organic despite reported flat guide | Watch |
| H2 TDAPA navigation | EUR 150–200M regulatory headwind; binder TDAPA mid-2026 | Q2 still pre-cliff; language on H2 is the tell | Risk (H2) |
| OI ex-SI path | Q1 EUR 467M · margin 10.1% | FY +/− MSD% vs EUR 2.212B base; H1 banks H2 | Watch |
| 5008X / HDF product mix | US clinic / treatment milestones ahead of plan (Q1 review) | Multi-year growth quality; immaterial to one quarter | Positive (LT) |
| Leverage / capital returns | Net leverage ~2.5x (low end of band); buyback ahead of schedule | Post-transformation optionality if savings deliver | Positive |
| US reimbursement / ACA | ACA ~EUR 50M within regulatory headwind; enrollment uncertainty | Structural debate; watch same-market treatment growth | Watch / risk |
Bull case
Organic ≥4%, savings beat linear, OI ex-SI solid, and H2 TDAPA language softens or is better absorbed → transition-year narrative de-risks and quality-healthcare re-rate can start.
Bear case
Organic slips, savings lag, same-market treatments stay soft, or H2 guide risk rises on TDAPA → value-trap narrative; ADR headline miss compounds optics even if ex-SI is only modestly soft.
Ex-earnings newsflow and sector color since the Q1 report (2026-05-05). The material driver remains transformation execution and US reimbursement / TDAPA path into H2.
| Date | Item | Earnings read-through |
|---|---|---|
| Ongoing | US dialysis reimbursement / VBC / TDAPA | Structural debate. Phosphate binder TDAPA mid-2026 roll-off is the known H2 negative; Q1 deliberately banked strength. CY2027 ESRD PPS rule path is the multi-quarter regulatory bridge. |
| Ongoing | FME25+ program updates | Execution scorecard each print. Q1 EUR 50M / EUR 250M is the bar; any slip is a credibility hit after years of FME25 delivery. |
| Peer | DaVita (DVA) US dialysis color | Best same-market / reimbursement read-through for Care Delivery. Cross-check US treatment growth vs FME Q1 softness. |
| May 5, 2026 | Q1: organic +3.9%, guide confirmed not raised | Sets the Aug 4 bar: reaffirm expected; underlying constructive if organic and OI ex-SI hold; headline ADR can still print soft. |
Read-through: newsflow is dominated by transformation and reimbursement structure, not incremental commercial shocks. That fits a HOLD / transition-year setup: the print is a checkpoint on organic + savings + H2 language, not a momentum catalyst. No thesis-breaking product, litigation, or demand shock has surfaced in the window.
FME has a long history of solid underlying / mixed headline prints. Q1'26 was the first visible ADR miss after a long beat streak — by design (specials + transition). Pattern: judge organic + OI ex-SI, not GAAP/ADR headline.
| Metric | Q2'25 | Q3'25 | Q4'25 | Q1'26 |
|---|---|---|---|---|
| Headline EPS (ADR / FMP) | Beat $0.52 vs $0.50 | Beat $0.64 vs $0.59 | Beat $0.83 vs $0.65 | Miss $0.53 vs $0.59 |
| Underlying (ex-SI / organic) | Solid | Solid | Solid | Ex-SI constructive |
| Quarter | Headline (ADR) | Street est. | Underlying read | Result |
|---|---|---|---|---|
| 2025 Q2 | $0.52 | $0.50 | Solid | Beat |
| 2025 Q3 | $0.64 | $0.59 | Solid | Beat |
| 2025 Q4 | $0.83 | $0.65 | Solid | Beat |
| 2026 Q1 | $0.53 | $0.59 | OI ex-SI +10% cc · org +3.9% | Miss (headline) |
Pattern verdict — mixed headline, solid ex-SI; transition-year miss risk is real. Into Aug 4, a clean ADR beat is possible but not the thesis test. Base case: organic holds LSD, savings stay on track, guide reaffirmed — with room for ADR headline noise. The risk to the setup is not one soft ADR print; it is organic slipping or H2 TDAPA language getting worse.
FMS into Aug 4 is a transformation checkpoint, not a momentum print. HOLD reflects a transition year where H2 TDAPA is harder and management has already refused to raise on Q1 strength. Attractive only if you underwrite FME25+ through 2027 and can tolerate headline optics.
| Scenario | Shape | Implication |
|---|---|---|
| Bull | Organic ≥4% + savings beat + softer H2 language | Re-rate toward quality healthcare begins |
| Base | In-line ADR / mixed headline + guide reaffirm; organic ~LSD | Range-bound; wait for H2 TDAPA proof |
| Bear | Organic soft + savings slip + H2 guide cut risk | Value-trap narrative reasserts |
Bottom line: HOLD. Not a momentum print — a transformation checkpoint. Trade organic + OI ex-SI + H2 TDAPA language, not the ADR EPS print vs ~$0.62. Flag ADR $ vs EUR on every Street number.